No benefit from stents with degradable plastic coating after heart attack

(© Image: Depositphotos)
(© Image: Depositphotos)

A recent study led by Inselspital, Bern University Hospital and the University of Bern shows that stents with a degradable polymer coating offer no long-term advantage over conventional stents. However, patients who consistently take their cholesterol-lowering medication have a lower risk of complications following stent implantation. The study thus underlines the importance of long-term drug therapy after a heart attack.

Stent implantation is one of the most frequently performed cardiology procedures worldwide. Stents are used to open narrowed coronary arteries and reduce the risk of a new heart attack. While the long-term results after stent implantation are positive in most cases, late complications occur in around 1-2 percent of patients each year. A common cause of these complications is a phenomenon known as neoatherosclerosis. Neoatherosclerosis occurs when new cholesterol deposits form in the inner lining of the stent, which can lead to a blockage of the stent. Preventing such neoatherosclerosis reduces the risk of stent complications years after implantation.

Differences in stent coating

Today’s stents are often coated with a drug that prevents the inner lining of the vessel from growing too much and clogging the stent. These drug-eluting stents have a thin layer of plastic (polymer) on the metal struts that releases the drug into the vessel wall. In some stents, this plastic layer remains permanently, while in other stents, known as ’stents with biodegradable polymer’, it dissolves by itself after a few months. It was previously hoped that the dissolution of the plastic layer would reduce inflammation in the vessel wall and thus reduce the risk of new deposits (neoatherosclerosis). However, it was unclear whether this was actually the case.

Comparison of stent types in heart attack patients

A comprehensive study led by Jonas Häner and Lorenz Räber from the Department of Cardiology at Inselspital Bern University Hospital in collaboration with six Japanese hospitals has now investigated this question. For the study, 239 heart attack patients were randomly treated with either a stent with a degradable coating or a stent with a permanent plastic coating. Three years later, the inside of the stents was examined in the cardiac catheterization laboratory using a high-resolution camera (optical coherence tomography) for signs of neoatherosclerosis. The results showed that neoatherosclerosis occurred with similar frequency in both groups (11.4 percent in the stents with degradable coating compared to 13.3 percent in the conventional stents). Stents with a degradable coating therefore offer no advantage over stents with a permanent plastic coating.

Long-term protection with statins

According to Prof. Räber, head of the cardiac catheterization laboratory, the study also revealed another interesting discovery: patients who took their cholesterol-lowering drugs (statins) regularly for three years were significantly less likely to develop new neoatherosclerosis in the stents than those who did not follow this therapy consistently (8.5 percent compared to 27.8 percent). These results are of great importance for the treatment of patients after a heart attack. While the choice of stent type may be less crucial, the study highlights the central role of consistent use of cholesterol-lowering drugs for long-term health. A stent alone is not enough to be completely cured. ’The results show how important it is for patients to keep an eye on their cholesterol levels after stent implantation,’ emphasizes Räber. ’Consistently lowering cholesterol is crucial to avoid complications later on.’ Dr. Häner, senior physician for interventional cardiology and co-author of the study adds: ’Proper aftercare is just as important as the procedure itself’.